For over 40 years, Novartis has contributed to Australian ophthalmology.1 By developing cutting-edge gene therapies, pharmaceuticals and other transformative technologies to address a broad spectrum of ophthalmic diseases and conditions, Novartis has benefitted over 134 million people around the world.2 In Australia, Novartis has a focus on eliminating blindness and visual impairment.1 It has invested $30 million in local clinical trials, funding 14 ophthalmology studies in the last three years alone.3
References: 1. Novartis data on file. 2. Novartis data on file. 3. Austrade. Clinical Trial Capability report 2017.
